Selecting optimal treatment in clinical trials using covariate information
Journal of Chronic DiseasesPublished 1 July 1977
David P. Byar, Donald K. Corle
Citations90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
By studying the combinations of covariates which lead to selection of the various treatments as optimal, this work makes recommendations of treatment for different kinds of patients.
Abstract
We are interested in the question 'which treatment is best for which kinds of patients?' rather than the classical question, 'which treatment is best overall?'. A survivorship function in which the hazard is a function of the covariates is fitted both for all treatments combined and for separate treatments. Likelihood ratio tests are used to detect significant treatment-covariate interactions. If there are none, we test for a best overall treatment. Otherwise we define an optimal treatment for each patient. By studying the combinations of covariates which lead to selection of the various treatments as optimal, we make recommendations of treatment for different kinds of patients.
Keywords
Mathematics
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
The Journal of UrologyPrediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging
2,227 Citations1974Donald F. Gleason, George T. Mellinger
BiometricsCovariance Analysis of Censored Survival Data
1,758 Citations1974N. E. Breslow
The use of regression models for making covariance adjustments in the comparsion of survival curves is illustrated by application to a clinical trial of maintenance therapy for childhood leukemia.
CancerThe veterans administration cooperative urological research group's studies of cancer of the prostate
598 Citations1973David P. Byar
The overall recommendation at present is that patients with prostatic cancer should not be treated until their symptoms require relief, and at that time it is recommended starting treatment with 1.0 mg DES daily.
BiometrikaMarginal likelihoods based on Cox's regression and life model
528 Citations1973John D. Kalbfleisch, Ross L. Prentice
BiometricsEstimation of Exponential Survival Probabilities with Concomitant Information
388 Citations1965Polly Feigl, Marvin Zelen
This paper presents a method of estimating survival distributions when the survival times are asstumed to follow simple exponential distributions, with a different parameter for eacli patient.
The Annals of StatisticsEmpirical Probability Plots and Statistical Inference for Nonlinear Models in the Two-Sample Case
352 Citations1974Kjell A. Doksum
CancerEstrogen treatment for cancer of the prostate.Early results with 3 doses of diethylstilbestrol and placebo
245 Citations1970John C. Bailar, David P. Byar
The 1.0-mg dose has been as effective as the 5.0‐mg dose in controlling the prostate cancer, but it does not seem to be associated with the excess risk of cardiovascular death.
BiometrikaExponential survivals with censoring and explanatory variables
208 Citations1973R. L. Prentice
Significance tests and statements of probabilistic inference are derived for covariate parameters and for the hazard function at average values of the covariate, extended to include a Weibull component in the hazard.
CancerIncidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate
151 Citations1970Clyde E. Blackard, RICHARD P. DOE +2 more
Patients treated with a 5.0‐mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non‐fatal cardiovascular disease when compared to placebo in all stages of prostatic cancer (p < 0.025).
International Journal of CancerStatistical methods for the identification and use of prognostic factors
137 Citations1974P. Armitage, Edmund A. Gehan
This is an expository paper which reviews the rationale for determining prognostic factors and the statistical methods for finding and allowing for such factors in the design and analysis of clinical studies.
BiometrikaA note on data-splitting for the evaluation of significance levels
126 Citations1975David Cox
BiometricsUse of Concomitant Variables and Incomplete Survival Information in the Estimation of an Exponential Survival Parameter
107 Citations1966Calvin Zippin, P. Armitage
The statistical model is extended to permit maximum likelihood estimation of the parameters of the linear regression where not all patients in a follow-up study have died by the end of the study.
BiometricsA Logistic-Exponential Model for Use with Response-Time Data Involving Regressor Variables
71 Citations1973Max H. Myers, Benjamin F. Hankey +1 more
A mathematical model utilizing the geometric distribution for analyzing time-toresponse data takes into account concomitant information by means of a multivariate logistic function and results in two distinct exponential models involving regressor variables.
JNCI Journal of the National Cancer InstituteAn Exponential Model Relating Censored Survival Data and Concomitant Information for Prostatic Cancer Patients2
52 Citations1974David P. Byar, Robert Huse +1 more
BiometricsSelecting Concomitant Variables Using a Likelihood Ratio Step-Down Procedure and a Method of Testing Goodness of Fit in an Exponential Survival Model
25 Citations1974Richard A. Greenberg, Steven Bayard +1 more
This work reanalyzed the VACURG data to obtain estimates of the parameters of eight variables felt to be important in predicting survival of patients with prostatic cancer and evaluated the fit of the model to the data.